Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long‐term follow‐up
A randomized placebo‐controlled, double‐blind, two‐period phase 1b trial that was conducted in 40 HCV genotype 1 patients and SVR achieved following narlaprevir and PEG‐IFN/RBV‐therapy was durable up to 32 months after the end of treatment.
Pharmacokinetics and Antiviral Activity of Phx1766, a Novel HCV Protease Inhibitor, Using An Accelerated Phase I Study Design
An overlapping, dose-adaptive single-dose and multiple-dose escalating design in HV and HCV-infected patients proved to be highly efficient in identifying a therapeutic dose of PHX1766.
Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients
Randomised clinical trial: anti‐viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV
- J. Bergmann, J. de Bruijne, H. Reesink
- Medicine, BiologyAlimentary Pharmacology and Therapeutics
- 1 August 2011
Aliment Pharmacol Ther 2011; 34: 443–453
Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7
Findings indicate that the viral load decline in chronic hepatitis C patients treated with the TLR7 agonist ANA773 is likely due to intrinsic differences in the induction of endogenous IFNs and IFN-stimulated gene products (IFN-α and IP-10) uponTLR7 ligation.
Unexplained Hyponatremia: Seek and You Will Find
The diagnosis of this case of unexplained hyponatremia was unexpected, but important because it was treatable and a diagnostic algorithm to guide clinicians who are confronted with similar cases is presented.
Travellers who are immunosuppressed should be stable, know how to manage their condition, be prepared to manage minor illnesses, and know when and how to seek medical advice abroad.
Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.
Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression.
In this subset of patients infected by hepatitis C virus with a history of depression and intravenous drug use, prophylaxis with escitalopram results in the most substantial decrease of interferon-induced depressive symptoms on the SCL-90 depression scale and the BDI.